跳至主要内容
临床试验/NCT06083896
NCT06083896招募中1 期

Minimally-invasive Stabilization of Pelvic Metastases With Photodynamic Nails: A Multi-center Prospective Study of Functional Outcome

M.D. Anderson Cancer Center1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2023年10月6日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
入组人数
50
试验地点
1
主要终点
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

研究概览

简要总结

Determine whether patients exhibit early functional improvement after minimally-invasive placement of Illuminoss photodynamic nails for peri-acetabular pelvic metastasis at 3 months following procedure

详细描述

Primary Objectives

1. Evaluate whether patients exhibit early functional improvement after minimally-invasive placement of Illuminoss photodynamic nails for peri-acetabular pelvic metastasis at 3 months following procedure

Secondary Objectives

  1. Evaluate whether the procedure relieves pain
  2. Evaluate radiographic stability of the implant
  3. Evaluate functional outcome at earlier time points (2 weeks or 6 weeks) and at 6 months and possibly later time points
  4. Evaluate reoperation rate and complications

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Patients must have a histologically confirmed malignancy from prior biopsy of the primary tumor or a metastatic site. Patients with carcinoma, myeloma, and lymphoma may be included in the study. Patients should have metastatic involvement of the periacetabular region that is visible radiographically. Biopsy of acetabular disease is not required for this study.
  • •Age ≥18 years (Illuminoss is approved only for skeletally mature patients)
  • •Suitable candidate for general anesthesia
  • •Ability to understand and the willingness to sign a written informed consent document.
  • •Able and willing to fill out pre-operative and post-operative functional outcome surveys
  • •Absolute neutrophil count ≥ 1,500/mcL
  • •Platelets ≥ 50,000/mcL

排除标准

  • •Patients with uncontrolled intercurrent illness (e.g., recent pneumonia or myocardial infarction that would significantly increase risk of general anesthesia)
  • •Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
  • •Patients with psychiatric illness/social situations that would limit compliance with study requirements.
  • •Pregnant women are excluded from this study because of the risk of general anesthesia and radiation exposure (fluoroscopy) to the fetus
  • •History of allergic reactions attributed to compounds of similar chemical or biologic composition to dental resins or PET.

结局指标

主要结局

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

时间窗: Through study completion, up to one year

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Minimally-invasive Stabilization of Pelvic... | 临床试验